Hereditary Renal Cell Carcinoma
Syndrome Gene Chromosome location Mutation rate in sporadic RCC Prevalence % de novo Renal tumor histology Multiple/solitary Penetrance of RCC Age (years) at RCC diagnosis Extrarenal manifestations VHL disease VHL…
Treatment Overview
Fig. 6.1 Treatment algorithm for nonmetastatic patients with RCC 6.2.1 Stage 1 6.2.1.1 Surgical Therapy Surgical therapy remains the mainstream treatment for patients with stage 1 RCC because the resection…
Optimization of Therapy by Pharmacokinetic–Pharmacodynamic Analyses
Drug Factor influencing PK PK/PD relationship PK parameter PD (efficacy, toxicity) Tyrosine kinase inhibitors Sorafenib C trough PFS Skin toxicity Hand-foot reaction Hypertension [3] AUCcum Any grade ≥ 3 toxicity…
Immunotherapy for Renal Cell Cancer (RCC)
Agent n Phase References Proleukin (IL-2) 255 Phase II Fyfe G. et al. [19] IFN-α 350 Meta-analysis Medical Research (vs medroxyprogesterone acetate) Council Renal Cancer Collaborators [22] IFN-α+ VLB 160…
Molecular Genetics of Renal Cell Carcinoma
Fig. 3.1 Molecular characterization of clear-cell renal cell carcinoma PBRM1 3.2.2 Mutations of Chromatin Enzymes The importance of chromatin dynamics and its dysregulation in tumorigenesis is increasingly appreciated since the…
Epidemiology of Renal Cell Carcinoma
Continents Incidence Mortality North America Male 15.5 3.7 Female 8.3 1.6 Both 11.7 2.6 Europe Male 12.3 4.8 Female 5.9 1.9 Both 8.8 3.1 Oceania Male 11.0 2.8 Female 5.3…
Forthcoming Drugs for Metastatic Renal Cell Carcinoma Therapy
Agent Molecular targets Phase (comparator) Patient population Clinical activity in RCC References Tivozanib (AV-951) VEGFR-1, 2, 3 Phase III (TIVO-1) (vs. sorafenib) Clear cell RCC PFS (11.9 vs. 9.1 mo)…
Refractory Mechanisms
© Springer Japan KK 2017Mototsugu Oya (ed.)Renal Cell Carcinoma10.1007/978-4-431-55531-5_15 15. Refractory Mechanisms Mototsugu Oya1 , Toshiaki Shinojima1 and Ryuichi Mizuno1 (1) Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan Mototsugu Oya Email:…
Treatment for Non-clear Cell Renal Cell Carcinoma
Author Study design Setting Population Treatment line Patients, n Patients with NCCRCC, n NCCRCC histologies Targeted agent Ratain et al. [5] 2 Metastatic RCC 2nd 152 15 PRCC Sorafenib Stadler…
Mammalian Targets of Rapamycin Inhibitors: Temsirolimus and Everolimus
Characteristic Temsirolimus Everolimus Study population Treatment-naive patients with poor-risk disease Patients who had progressed on prior sunitinib and/or sorafenib Number of patients 626 410 Randomization Temsirolimus vs. temsirolimus/IFN-α vs. IFN-α…
